PowerShares Dynamic Biotechnology & Genome Portfolio is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the price and yield of the Dynamic Biotechnology & Genome Intellidex Index a fundamentally-weighted index. Securities shown to possess the greatest capital appreciation potential are selected by the Index.

Performance

TODAY	1 DAY	5 DAY	10 DAY	1 MO	3 MO	6 MO	1 YR	2 YR	5 YR
-1.9%	-1.9%	-0.3%	0.8%	-2.3%	11.6%	23.2%	27.9%	33.7%	64.3%

Technical

ALPHA	BETA	R2	STD DEV
0.0057	0.948	0.603	0.065

• Choosing the Right Biotech ETF Exposure

  04-20-2012 03:09 PM by Tom Lydon

  Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...

  Read more

• Biotech ETFs Mixed After Gilead Subpoena

  06-13-2011 01:53 PM by Tom Lydon

  Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...

  Read more

• 5 Biotechnology ETFs to Play Innovation

  02-22-2011 02:00 PM by Tom Lydon

  While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...

  Read more

• Why Health Care ETFs May Be In the Clear

  11-10-2010 11:00 AM by Tom Lydon

  After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don't believe there's anything to worry about for a while. First, with most corporations backi...

  Read more

• 5 Things That Drive Biotech ETFs

  10-21-2010 03:00 PM by Tom Lydon

  The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here's what drives the sector and exchange traded funds (ETFs) that let you play it. Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven...

  Read more

• Biotech ETFs:The Better Way to Play

  10-11-2010 06:00 AM by Tom Lydon

  As cash-strapped biotech companies see their cash reserves dwindle, it  has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech exchange traded funds (ETFs). The number of publicly-t...

  Read more

• Biotech ETFs: 5 Ways to Play Innovation

  08-08-2010 01:00 PM by Tom Lydon

  Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...

  Read more

• 5 Biotech ETFs If You're Bullish

  06-25-2010 01:00 AM by Tom Lydon

  Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if you're looking for a more diversified and steady approach to biotech investing, look no further than exchange traded f...

  Read more

• Biotech ETFs: Where the Future Lies

  02-05-2010 02:00 PM by Tom Lydon

  Biotechnology is continuously advancing and the future may lie in personalized medicine. The biotech sector, along with related exchange traded funds (ETFs), may see billions in revenue as this market grows in the coming years. Biotech companies, investors, providers and big p...

  Read more

• Biotechnology: Why ETFs Suit the Sector

  11-19-2009 02:00 PM by Tom Lydon

  The biotechnology sector is once again finding its footing, with some exchange traded funds (ETFs) focused on the sector up more than 30% since the market's March 9 low. But there have been stumbling blocks on the way back to profitability. A reputable biotechnology company h...

  Read more

• What Biotechnology ETFs Need to Thrive

  09-04-2009 02:00 PM by Tom Lydon

  The biotechnology sector and its related exchange traded funds (ETFs) have seen a handsome rebound off the March 9 lows, but does the cash-strapped sector have what it takes to survive for the long haul? Analysts estimate that nearly half of all biotechnology firms have insuf...

  Read more

• 7 Reasons Biotechnology ETFs Could Succeed

  08-06-2009 01:00 AM by Tom Lydon

  The biotechnology sector and exchange traded funds (ETFs) have had a good summer so far. Some funds are up as much as 22% in the last month alone. Will it continue? July was kind to the biotech sector. The NYSE Biotechnology Sector rose up 24%, which dwarfed the 6% for the S&a...

  Read more

• ETF Spotlight: PowerShares Dynamic Biotech & Genome (PBE)

  07-29-2009 02:00 PM by Tom Lydon

  ETF Spotlight on PowerShares Dynamic Biotech & Genome (PBE), part of a weekly series. Assets: $148 million Holdings: This fund invests in companies involved in the biotechnology and genome sectors. Some of the top components include ImmunoGen (IMGN), Amgen (AMGN), Gilead S...

  Read more

• Biotech Sector and ETFs Get a Lifeline

  07-08-2009 12:00 PM by Tom Lydon

  A small piece of the 2009 Economic Stimulus Package will revamp aid to small businesses, which could give way to successful relationships between  small pharmaceutical/biotech companies and academic institutions. This may be what related investments and exchange traded funds (ET...

  Read more

• Health Care Reform and Biotech ETFs: Will There Be Opportunities?

  06-27-2009 01:00 AM by Tom Lydon

  In an attempt to reduce costs in the health care industry, the government will be legislating for cheaper drugs, but drug makers, along with related exchange traded funds (ETFs), may see profits slip away. The Obama administration claims that biologic drugs should be subject t...

  Read more

• Why Biotech ETFs May Be the Better Choice

  06-17-2009 11:00 AM by Tom Lydon

  Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...

  Read more

• Can Obama's Push Reignite Biotech and Health Care ETFs?

  06-15-2009 12:00 PM by Tom Lydon

  Biotechnology and health care-related exchange traded funds (ETFs) could be set to take off as both sectors are in a transition period  and are gaining more support from the Obama administration. President Barack Obama today met with the American Medical Association about his...

  Read more

• Health Care ETFs' $140 Billion Boost

  02-19-2009 06:00 AM by Tom Lydon

  When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...

  Read more

• PowerShares' ETF Family Grows With Biotech, Commodities

  09-18-2008 12:00 PM by Tom Lydon

  The PowerShares exchange traded fund (ETF) family is adding a slew of new members this week. The PowerShares Global Biotech Portfolio (PBTQ) covers the growth of this industry. The biotech industry has seen increasing growth and revenue base over the past two years. No single ...

  Read more

• Genentech Holds Out for Better Offer, Which Could Deliver a Boost to Biotech ETFs

  08-14-2008 01:00 PM by Tom Lydon

  Biotechnology stocks and exchange traded funds (ETFs) could get a shot in the arm, as Genentech (DNA) rejected a takeover bid from Roche, which they feel has undervalued the company. Roche, the Swiss pharmaceutical company, offered Genentech an initial bid of $43.7 billion, wh...

  Read more

• Biotech ETFs Are a Matter of Personal Choice

  07-27-2008 01:00 AM by Tom Lydon

  Biotechnology appeals to many investors, and with four different exchange traded funds (ETFs) focused on the class, is there a fund that is better than the rest? The sector is one of the few non-commodity related that's solidly above its trend line. Each of the four ETFs wi...

  Read more

• Biotechnology ETFs Growing...Like Genetically Modified Crops?

  07-16-2008 11:00 AM by Tom Lydon

  Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...

  Read more

Number of Holdings: 30

%	Ticker	Name	Sector	Market Cap	Country
5.3%	WAT	Waters Corp	Other	8429970000	United States
5.1%	ILMN	Illumina Inc	LIFE SCIENCES TOOLS & SERVICES	8705250000	United States
5.1%	LIFE	Life Technologies Co...	Real Estate	12750920000	United States
5.0%	AMGN	Amgen Inc	Technology	74107500000	United States
4.9%	REGN	Regeneron Pharmaceut...	Technology	25239530000	United States
4.8%	GILD	Gilead Sciences Inc	Technology	80679120000	United States
4.5%	BIIB	Biogen Idec Inc	Technology	53414080000	United States
2.9%	ISIS	Isis Pharmaceuticals...	Technology	2556250000	United States
2.9%	VPHM	ViroPharma Inc	Health Care	1775810000	United States
2.9%	CADX	Cadence Pharmaceutic...	Health Care	637510000	United States

Members see all holdings. Not a member yet? Click here to join.